Literature DB >> 8198985

Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy.

C J Twelves1, D A Porter, M Lowry, N A Dobbs, P E Graves, M A Smith, R D Rubens, M A Richards.   

Abstract

We have studied the metabolism of 31P-containing metabolites of post-menopausal breast cancers in vivo using magnetic resonance spectroscopy (MRS) and a 5.5 cm surface coil. Spectra were acquired from 23 diameter. The spectra of the 19 previously untreated tumours had significantly higher phosphomonoester (PME) 31P relative peak areas than the normal breasts of eight post-menopausal women (11.7% and 7.7% respectively, P = 0.002). Although an increased PME relative peak area was characteristic of malignancy, PME relative peak area is similarly raised in lactating breast and, therefore, not a specific feature of cancer. An apparently lower nucleotide triphosphate (NTP) relative peak area in tumours than healthy postmenopausal breast was secondary to the differences in PME relative peak area; contamination by signal from chest wall muscle probably accounts for the ostensibly higher phosphocreatine (PCr) relative peak area of the tumours. Spectroscopy was repeated following chemotherapy in six women. An increase in PCr relative peak area was seen in all five patients who responded, but again this may represent increased contamination secondary to changes in tumour size. A fall in PME relative peak area was noted in four responders, but also one non-responder, so this finding may not be sufficiently specific to be of use clinically. Further studies are need to elucidate fully the role of MRS in breast cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8198985      PMCID: PMC1969456          DOI: 10.1038/bjc.1994.226

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer.

Authors:  J Glaholm; M O Leach; D J Collins; J Mansi; J C Sharp; A Madden; I E Smith; V R McCready
Journal:  Lancet       Date:  1989-06-10       Impact factor: 79.321

2.  An automated iterative algorithm for the quantitative analysis of in vivo spectra based on the simplex optimization method.

Authors:  R E Lenkinski; T Allman; J D Scheiner; S N Deming
Journal:  Magn Reson Med       Date:  1989-06       Impact factor: 4.668

3.  Differences in phosphate metabolite levels in drug-sensitive and -resistant human breast cancer cell lines determined by 31P magnetic resonance spectroscopy.

Authors:  J S Cohen; R C Lyon; C Chen; P J Faustino; G Batist; M Shoemaker; E Rubalcaba; K H Cowan
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

4.  Observation of tissue metabolites using 31P nuclear magnetic resonance.

Authors:  D I Hoult; S J Busby; D G Gadian; G K Radda; R E Richards; P J Seeley
Journal:  Nature       Date:  1974-11-22       Impact factor: 49.962

5.  Mapping of metabolites in whole animals by 31P NMR using surface coils.

Authors:  J J Ackerman; T H Grove; G G Wong; D G Gadian; G K Radda
Journal:  Nature       Date:  1980-01-10       Impact factor: 49.962

6.  Breast tumors: evaluation with P-31 MR spectroscopy.

Authors:  H Degani; A Horowitz; Y Itzchak
Journal:  Radiology       Date:  1986-10       Impact factor: 11.105

7.  Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T.

Authors:  P E Sijens; H K Wijrdeman; M A Moerland; C J Bakker; J W Vermeulen; P R Luyten
Journal:  Radiology       Date:  1988-12       Impact factor: 11.105

8.  Therapeutic response of breast carcinoma monitored by 31P MRS in situ.

Authors:  T C Ng; S Grundfest; S Vijayakumar; N J Baldwin; A W Majors; I Karalis; T F Meaney; K H Shin; F J Thomas; R Tubbs
Journal:  Magn Reson Med       Date:  1989-04       Impact factor: 4.668

9.  Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas.

Authors:  J L Evelhoch; N A Keller; T H Corbett
Journal:  Cancer Res       Date:  1987-07-01       Impact factor: 12.701

10.  31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues.

Authors:  T E Merchant; L W Gierke; P Meneses; T Glonek
Journal:  Cancer Res       Date:  1988-09-15       Impact factor: 12.701

View more
  6 in total

1.  A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts.

Authors:  Ting Liu; Kavindra Nath; Weixia Liu; Rong Zhou; I-Wei Chen
Journal:  NMR Biomed       Date:  2015-07-14       Impact factor: 4.044

2.  CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response.

Authors:  Kannie W Y Chan; Lu Jiang; Menglin Cheng; Jannie P Wijnen; Guanshu Liu; Peng Huang; Peter C M van Zijl; Michael T McMahon; Kristine Glunde
Journal:  NMR Biomed       Date:  2016-04-21       Impact factor: 4.044

3.  Human in-vivo 31P MR spectroscopy of benign and malignant breast tumors.

Authors:  J M Park; J H Park
Journal:  Korean J Radiol       Date:  2001 Apr-Jun       Impact factor: 3.500

4.  Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  N R Jagannathan; M Kumar; V Seenu; O Coshic; S N Dwivedi; P K Julka; A Srivastava; G K Rath
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

5.  Detection of alterations in membrane metabolism during neoadjuvant chemotherapy in patients with breast cancer using phosphorus magnetic resonance spectroscopy at 7 Tesla.

Authors:  Wybe Jm van der Kemp; Bertine L Stehouwer; Peter R Luijten; Maurice Aaj van den Bosch; Dennis Wj Klomp
Journal:  Springerplus       Date:  2014-10-27

Review 6.  Magnetic resonance in the detection of breast cancers of different histological types.

Authors:  Rebecca M Mayrhofer; Hsiao Piau Ng; Thomas C Putti; Philip W Kuchel
Journal:  Magn Reson Insights       Date:  2013-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.